AbbVie already has a working relationship with Gilgamesh, in the form of an R&D collaboration and opt-in licensing agreement ...

When Tidmarsh was appointed to CDER, the FDA emphasised his academic and clinical credentials – including his role as ...

The problem of medical misinformation on the Internet was brewing before the COVID-19 pandemic, but the combustible discourse ...

Many LSHC GCCs handle functions like clinical trials and operations, which mandate high regulatory scrutiny and explainability of the data generated. Sovereign AI makes this possible by allowing full ...

AI, automation, and machine learning all have the potential to impact the customer experience – for both patients and HCPs – ...

Venclexta has been on the market since 2016 for CLL, initially for 17p-mutated cases, and since 2019 has been used as a first ...

The algorithm, developed by AI specialist Lunit, was retrospectively tested in conjunction with an advanced 3D mammography ...

At the Axtria Ignite 2025 conference, web editor Nicole Raleigh spoke with Mark Montgomery, VP & international head, ...

GSK has become the latest drugmaker to run into difficulties in developing a drug targeting the immune checkpoint receptor ...

Roberts has been at the helm of NICE for four years, taking over in February 2022 after the departure of Prof Gillian Leng, who decided to step down after the death of her husband, former Public ...

There was consternation among the research community yesterday after it emerged that the White House's Office of Management ...

Vinay Prasad has stepped down as head of the FDA's Center for Biologics Evaluation and Research (CBER), less than three ...